Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

OBJECTIVE: Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates for heart failure (HF). However, the mechanisms behind these benefits are not ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Leccisotti, Lucia, Cinti, Francesca, Sorice, Gian Pio, D’Amario, Domenico, Lorusso, Margherita, Guzzardi, Maria Angela, Mezza, Teresa, Gugliandolo, Shawn, Cocchi, Camilla, Capece, Umberto, Indovina, Luca, Ferraro, Pietro Manuel, Iozzo, Patricia, Crea, Filippo, Giordano, Alessandro, Giaccari, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440459/
https://www.ncbi.nlm.nih.gov/pubmed/36057768
http://dx.doi.org/10.1186/s12933-022-01607-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440459/
https://www.ncbi.nlm.nih.gov/pubmed/36057768
http://dx.doi.org/10.1186/s12933-022-01607-4

Ejemplares similares